John M. Burke, MD, Rocky Mountain Cancer Centers
Articles
Evolving Therapies in R/R DLBCL: Concluding Remarks
Ian Flinn, MD, PhD, Sarah Cannon Research Institute;John M. Burke, MD, Rocky Mountain Cancer Centers;Kami Maddocks, MD, The Ohio State University;Amitkumar Mehta, MD, O'Neal Comprehensive Cancer Center at UAB;Loretta J. Nastoupil, MD, MD Anderson Cancer Center
March 26th 2021Read More
R/R DLBCL: A Glance at Using Novel Therapies Moving Forward
Ian Flinn, MD, PhD, Sarah Cannon Research Institute;John M. Burke, MD, Rocky Mountain Cancer Centers;Kami Maddocks, MD, The Ohio State University;Amitkumar Mehta, MD, O'Neal Comprehensive Cancer Center at UAB;Loretta J. Nastoupil, MD, MD Anderson Cancer Center
March 26th 2021Read More
R/R DLBCL: Novel Therapies in the Pipeline
Ian Flinn, MD, PhD, Sarah Cannon Research Institute;John M. Burke, MD, Rocky Mountain Cancer Centers;Kami Maddocks, MD, The Ohio State University;Amitkumar Mehta, MD, O'Neal Comprehensive Cancer Center at UAB;Loretta J. Nastoupil, MD, MD Anderson Cancer Center
March 26th 2021Read More
Treating Primary Refractory DLBCL
Ian Flinn, MD, PhD, Sarah Cannon Research Institute;John M. Burke, MD, Rocky Mountain Cancer Centers;Kami Maddocks, MD, The Ohio State University;Amitkumar Mehta, MD, O'Neal Comprehensive Cancer Center at UAB;Loretta J. Nastoupil, MD, MD Anderson Cancer Center
March 19th 2021Read More
R/R DLBCL: Transplants in the Era of CAR-T
Ian Flinn, MD, PhD, Sarah Cannon Research Institute;John M. Burke, MD, Rocky Mountain Cancer Centers;Kami Maddocks, MD, The Ohio State University;Amitkumar Mehta, MD, O'Neal Comprehensive Cancer Center at UAB;Loretta J. Nastoupil, MD, MD Anderson Cancer Center
March 12th 2021Read More
CAR T for R/R DLBCL: Improving Access and Utilization
Ian Flinn, MD, PhD, Sarah Cannon Research Institute;John M. Burke, MD, Rocky Mountain Cancer Centers;Kami Maddocks, MD, The Ohio State University;Amitkumar Mehta, MD, O'Neal Comprehensive Cancer Center at UAB;Loretta J. Nastoupil, MD, MD Anderson Cancer Center
March 12th 2021Read More
CAR T for R/R DLBCL: Safety/Tolerability
Ian Flinn, MD, PhD, Sarah Cannon Research Institute;John M. Burke, MD, Rocky Mountain Cancer Centers;Kami Maddocks, MD, The Ohio State University;Amitkumar Mehta, MD, O'Neal Comprehensive Cancer Center at UAB;Loretta J. Nastoupil, MD, MD Anderson Cancer Center
March 5th 2021Read More
Understanding the CAR-T Process: Collection Through Infusion
Ian Flinn, MD, PhD, Sarah Cannon Research Institute;John M. Burke, MD, Rocky Mountain Cancer Centers;Kami Maddocks, MD, The Ohio State University;Amitkumar Mehta, MD, O'Neal Comprehensive Cancer Center at UAB;Loretta J. Nastoupil, MD, MD Anderson Cancer Center
March 5th 2021Read More
Treating R/R DLBCL With CAR-T: Current Barriers
Ian Flinn, MD, PhD, Sarah Cannon Research Institute;John M. Burke, MD, Rocky Mountain Cancer Centers;Kami Maddocks, MD, The Ohio State University;Amitkumar Mehta, MD, O'Neal Comprehensive Cancer Center at UAB;Loretta J. Nastoupil, MD, MD Anderson Cancer Center
February 26th 2021Read More
CAR-T Treatment Options for R/R DLBCL
Ian Flinn, MD, PhD, Sarah Cannon Research Institute;John M. Burke, MD, Rocky Mountain Cancer Centers;Kami Maddocks, MD, The Ohio State University;Amitkumar Mehta, MD, O'Neal Comprehensive Cancer Center at UAB;Loretta J. Nastoupil, MD, MD Anderson Cancer Center
February 26th 2021Read More
CAR T-Cell Therapy for R/R DLBCL
Ian Flinn, MD, PhD, Sarah Cannon Research Institute;John M. Burke, MD, Rocky Mountain Cancer Centers;Kami Maddocks, MD, The Ohio State University;Amitkumar Mehta, MD, O'Neal Comprehensive Cancer Center at UAB;Loretta J. Nastoupil, MD, MD Anderson Cancer Center
February 19th 2021Read More
R/R DLBCL: Treating With Tafasitamab-Lenalidomide
Ian Flinn, MD, PhD, Sarah Cannon Research Institute;John M. Burke, MD, Rocky Mountain Cancer Centers;Kami Maddocks, MD, The Ohio State University;Amitkumar Mehta, MD, O'Neal Comprehensive Cancer Center at UAB;Loretta J. Nastoupil, MD, MD Anderson Cancer Center
February 12th 2021Read More
Tafasitamab Combined With Lenalidomide in R/R DLBCL
Ian Flinn, MD, PhD, Sarah Cannon Research Institute;John M. Burke, MD, Rocky Mountain Cancer Centers;Kami Maddocks, MD, The Ohio State University;Amitkumar Mehta, MD, O'Neal Comprehensive Cancer Center at UAB;Loretta J. Nastoupil, MD, MD Anderson Cancer Center
February 12th 2021Read More
R/R DLBCL: Second-Line Treatment Options
Ian Flinn, MD, PhD, Sarah Cannon Research Institute;John M. Burke, MD, Rocky Mountain Cancer Centers;Kami Maddocks, MD, The Ohio State University;Amitkumar Mehta, MD, O'Neal Comprehensive Cancer Center at UAB;Loretta J. Nastoupil, MD, MD Anderson Cancer Center
February 5th 2021Read More
DLBCL: Treating Patients Following Relapse on Frontline Therapy
Ian Flinn, MD, PhD, Sarah Cannon Research Institute;John M. Burke, MD, Rocky Mountain Cancer Centers;Kami Maddocks, MD, The Ohio State University;Amitkumar Mehta, MD, O'Neal Comprehensive Cancer Center at UAB;Loretta J. Nastoupil, MD, MD Anderson Cancer Center
February 5th 2021Read More
DLBCL: Treatment Considerations for Challenging Populations
Ian Flinn, MD, PhD, Sarah Cannon Research Institute;John M. Burke, MD, Rocky Mountain Cancer Centers;Kami Maddocks, MD, The Ohio State University;Amitkumar Mehta, MD, O'Neal Comprehensive Cancer Center at UAB;Loretta J. Nastoupil, MD, MD Anderson Cancer Center
January 29th 2021Read More
DLBCL: Circumstances for Deviating Away From R-CHOP
Ian Flinn, MD, PhD, Sarah Cannon Research Institute;John M. Burke, MD, Rocky Mountain Cancer Centers;Kami Maddocks, MD, The Ohio State University;Amitkumar Mehta, MD, O'Neal Comprehensive Cancer Center at UAB;Loretta J. Nastoupil, MD, MD Anderson Cancer Center
January 29th 2021Read More
Latest Updated Articles
Published: December 3rd 2024 | Updated: December 6th 2024
ASH 2024 Preview for Medical Oncologists: The Show and After Show
Published: October 30th 2024 | Updated: November 7th 2024
Phase 1/2 ALKOVE-1 Study of NVL-655 in ALK-positive (ALK+) Solid Tumors
Published: October 18th 2024 | Updated: October 21st 2024
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)
Published: October 14th 2024 | Updated: October 16th 2024
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Published: September 27th 2024 | Updated: October 9th 2024
Petosemtamab Plus Pembrolizumab vs. Pembrolizumab Alone for First-Line (1L) Treatment of Recurrent/Metastatic (R/M) PD-L1–Positive Head and Neck Squamous Cell Carcinoma (HNSCC): A Randomized, Open-Label, Phase 3 Trial
Published: September 30th 2024 | Updated: October 4th 2024
Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer
